One stock that might be an intriguing choice for investors right now is Albireo Pharma, Inc. ALBO. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug ...

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a ...

Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) is acquiring Albireo (NASDAQ:ALBO) in deal worth about $952M plus one contingent value right (CVR) per share to bolster its rare disease portfolio with treatments for ...

Ipsen has set aside the two drug candidates it picked up from the 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely. While the prize of the $952 ...

Ipsen’s near-$1 billion deal for Albireo was among a trio of biopharma acquisitions that opened this year’s J.P. Morgan Healthcare Conference. But Ipsen only got a chance to bid thanks to a sudden ...

– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome – – EMA & FDA reviewing odevixibat ...

BOSTON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the ...

The regulator on Tuesday approved odevixibat, an Albireo Pharma drug developed to treat severe itching, or pruritus, in patients who have the liver disorder progressive familial intrahepatic ...

Albireo Energy, a leading independent building controls and energy services provider and Huron Capital portfolio company, has been Certified™ by Great Place To Work® for the eighth year in a row. This ...